Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common steroid gel quiet oral lichen planus by altering MicroRNAs?

NCT ID NCT05818618

Disease control Sponsor: University of Catania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This trial investigates whether a topical clobetasol gel can change the levels of microRNAs in the gum fluid of people with oral lichen planus, a chronic inflammatory condition. Participants will apply either the active gel or a placebo to their lesions, and researchers will compare miRNA levels and symptom severity before and after treatment. The goal is to see if these molecular changes could serve as early indicators of disease activity or treatment response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clobetasol topical gel
What this could lead to
If clobetasol shifts miRNA levels, it could point toward a way to monitor or treat oral lichen planus more effectively.
What could go wrong
This is a small, early-stage trial, so results may not be conclusive. Clobetasol can cause local irritation or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

62 people

The number who actually took part.

Started

Mar 2020

Finished

Aug 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The complete correspondence of the most recent WHO clinical and histopathological criteria (2020) for OLP diagnosis. Exclusion Criteria: * 1\) Previous therapies for OLP during the last six months preceding the study; 2) State of pregnancy or breastfeeding; 3) Contact or drug oral lichenoid lesions; 4) Allergies to the molecules used in the study; 5) HIV seropositivity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Oral lichen planus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lichen planus, oral

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Oral lichen planus

Contacts and locations

Locations

  • AOU Policlinico G. Rodolico

    Catania, Catania, 95124, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.